TScan Therapeutics' (TCRX) "Outperform" Rating Reaffirmed at Wedbush

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "outperform" rating reaffirmed by stock analysts at Wedbush in a research note issued on Monday, RTT News reports. They currently have a $10.00 price target on the stock. Wedbush's price target would suggest a potential upside of 24.84% from the stock's current price.

TCRX has been the subject of several other research reports. Needham & Company LLC restated a "buy" rating and set a $11.00 price target on shares of TScan Therapeutics in a research report on Monday. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 7th.

TScan Therapeutics Stock Up 3.6 %

Shares of NASDAQ:TCRX traded up $0.28 during midday trading on Monday, reaching $8.01. The company's stock had a trading volume of 149,406 shares, compared to its average volume of 182,728. The firm has a market capitalization of $383.52 million, a P/E ratio of -4.24 and a beta of 0.91. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.18. TScan Therapeutics has a 12-month low of $1.93 and a 12-month high of $9.09. The firm has a 50 day moving average of $7.46 and a 200-day moving average of $6.19.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. The firm had revenue of $7.21 million during the quarter, compared to analysts' expectations of $2.94 million. On average, research analysts anticipate that TScan Therapeutics will post -1.03 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

Several hedge funds have recently added to or reduced their stakes in TCRX. Vanguard Group Inc. raised its position in TScan Therapeutics by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company's stock worth $14,357,000 after acquiring an additional 20,000 shares during the period. Tocqueville Asset Management L.P. purchased a new position in shares of TScan Therapeutics during the 1st quarter worth $1,685,000. abrdn plc purchased a new stake in shares of TScan Therapeutics in the 4th quarter valued at $1,166,000. Letko Brosseau & Associates Inc. purchased a new position in shares of TScan Therapeutics in the 3rd quarter valued at about $83,000. Finally, Pale Fire Capital SE raised its position in shares of TScan Therapeutics by 30.2% during the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company's stock worth $126,000 after acquiring an additional 4,998 shares in the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.